Mounjaro (Tirzepatide) — Complete UK Guide
What is Mounjaro?
Mounjaro (tirzepatide) is a prescription weight loss medication approved for use in the UK. It belongs to a new class of dual-action drugs that target both GIP and GLP-1 receptors, making it one of the most effective weight loss treatments available.
How does it work?
Mounjaro is a dual GIP and GLP-1 receptor agonist. It works by mimicking two natural hormones that regulate blood sugar and appetite. This dual action reduces appetite, slows gastric emptying, and helps the body use insulin more effectively — leading to significant weight loss.
AdGPhC-registered, same-day prescription, next-day delivery from EverydayMeds.
Mounjaro doses & expected weight loss
Based on SURMOUNT-1 trial data over 72 weeks
| Dose | Avg Weight Loss | Notes |
|---|---|---|
| 2.5mg | ~5% | Starting dose — weeks 1–4 |
| 5mg | ~9% | First escalation — weeks 5–8 |
| 7.5mg | ~12% | Weeks 9–12 |
| 10mg | ~14% | Weeks 13–16 |
| 12.5mg | ~16% | Weeks 17–20 |
| 15mg | ~20.9% | Maximum dose — maintenance |
Dose escalation timeline
Who is eligible?
- BMI of 30 or above (obese)
- BMI of 27.5 or above with a weight-related health condition
- BMI of 23 or above for South Asian patients (adjusted threshold)
- Must be aged 18 or over
Clinically BackedWeight Loss
Same-day prescription from a GPhC-registered UK pharmacy. Next-day DPD delivery. From £144.99.
Side effects
- Nausea (most common, usually improves)
- Diarrhoea
- Constipation
- Vomiting
- Decreased appetite
- Abdominal pain
- Injection site reactions
Most side effects are mild and improve as your body adjusts to the medication.
Mounjaro vs Wegovy
| Feature | Mounjaro | Wegovy |
|---|---|---|
| Drug name | Tirzepatide | Semaglutide |
| Mechanism | Dual GIP + GLP-1 | GLP-1 only |
| Max weight loss | ~20.9% | ~14.9% |
| Max dose | 15mg weekly | 2.4mg weekly |
| Administration | Weekly injection | Weekly injection |
| FDA approved | 2023 | 2021 |